The EU butts heads with Big Pharma to make medicines cheaper

By HEOR Staff Writer

February 2, 2023

The new EU proposal to revamp its pharmaceutical regulations. The main aim is to give people a better and more affordable access to medicines.

From what I can see, there are mixed feelings about the proposal. On one hand, consumer groups and civil society organizations are applauding the EU’s efforts to make medicines more accessible. On the other hand, the pharmaceutical industry is a bit skeptical.

So, what’s in the proposal? Well, the EU is looking to shorten the period in which pharmaceutical companies can sell their medicines without competition from 10 years to just 8 years. They’re also working towards closing the gap in access to medicines among different EU member states.

It’s interesting to see how this will all play out. What are your thoughts on the EU Pharmaceutical Regulations Proposal?

Reference url

Recent Posts

Enhancing Systematic Reviews: AI Literature Review Integration for Efficiency and Rigor

By João L. Carapinha

February 23, 2026

AI Literature Review Integration is transforming systematic literature reviews (SLRs), as outlined in this preprint. It provides methodological guidance for incorporating artificial intelligence (AI) into SLRs with a human-in-the-loop approa...
Administrative Court Error Complicates Infarmed Vaccine Data Transparency

By João L. Carapinha

Court Clerical Error Threatens Infarmed Vaccine Data Transparency Infarmed vaccine data transparency hangs in the balance due to a clerical error by the Lisbon Administrative Court's secretariat, which sent a January...
EMA Executive Director Recruitment: Leading the Future of Medicines Regulation

By João L. Carapinha

The EMA Executive Director Recruitment procedure has opened, a pivotal role overseeing operations like medicine authorizations, safety monitoring, and EU-wide public health responses. This vacancy, with reference COM/2026/20118, reports to the EMA Management Board, managing a 2025 budget of about...